Corcept Therapeutics (CORT) has submitted a new drug application to the FDA for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics presents results from relacorilant study
- Corcept Therapeutics says CATALYST trial met primary endpoint
- Corcept says DAZALS study did not meet primary endpoint
- Corcept Therapeutics price target raised to $73.50 from $72 at Ladenburg
- Corcept Therapeutics Reports Strong Q3 Results and Positive Trial Outcomes